CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on November 2, 2005
Clinical Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.2215/CJN.00090605
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.00090605v1
1/1/100    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, K. A.
Right arrow Articles by Isbel, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, K. A.
Right arrow Articles by Isbel, N. M.

Received June 3, 2005
Accepted on August 16, 2005

Original Articles

Should an Oral Glucose Tolerance Test Be Performed Routinely in All Renal Transplant Recipients?

Kirsten A. Armstrong *1, Johannes B. Prins {dagger}, Elaine M. Beller {ddagger}, Scott B. Campbell *, Carmel M. Hawley *, David W. Johnson *, and Nicole M. Isbel *

Departments of *Nephrology and {dagger}Endocrinology and {ddagger}School of Population Health, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia


1 To whom correspondence should be addressed. E-mail: kirsty{at}ascom.net.


   Abstract

Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG <126 mg/dl (7.0 mmol/L; n = 188) underwent an oral glucose tolerance test (OGTT). Receiver operating characteristic analyses evaluated the optimal level of FBG predictive of PTD (2HBG ≥200 mg/dl [11.1 mmol/L]) and impaired glucose tolerance (IGT; 2HBG 140 to 200 mg/dl [7.8 to 11.0 mmol/L]). An abnormal OGTT was reported in 79 (42%) nondiabetic RTR: PTD (n = 22) and IGT (n = 57). The optimal FBG that was predictive of PTD was 101 mg/dl (5.6 mmol/L; area under the curve 0.70; sensitivity 64%, specificity 67%, positive predictive value 20%, negative predictive value 93%). The optimal FBG that was predictive of IGT was less well defined (area under the curve 0.54). The prevalence of PTD was higher by OGTT than by FBG alone (17 versus 6%; P < 0.001). FBG may not be the optimal screening or diagnostic tool for PTD or IGT in RTR. Consideration should be given to introducing the OGTT as a routine posttransplantation investigation, although the implications of a pathologic OGTT are still to be determined in this population.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
H. W. Chan, C. Y. Cheung, Y. L. Liu, Y. H. Chan, H. S. Wong, W. L. Chak, K. S. Choi, K. F. Chau, and C. S. Li
Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study
Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3337 - 3342.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
P. Delgado, J. M. Diaz, I. Silva, J. M. Osorio, A. Osuna, B. Bayes, R. Lauzurica, E. Arellano, J. M. Campistol, R. Dominguez, et al.
Unmasking Glucose Metabolism Alterations in Stable Renal Transplant Recipients: A Multicenter Study
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 808 - 813.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
A. C. Shirali and M. J. Bia
Management of Cardiovascular Disease in Renal Transplant Recipients
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
R. D. Bloom and M. F. Crutchlow
New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Society of Nephrology.